Is it necessary to take rasagiline? Which patients are suitable for use?

Whether rasagiline is "necessary" depends on the patient's stage of Parkinson's disease and its clinical manifestations. As a selective MAO-B inhibitor, rasagiline's main function is to delay the degradation of dopamine in the brain, thereby alleviating the movement disorder symptoms of Parkinson's disease. The advantage of this type of drug is that it has relatively few side effects and is convenient to administer once a day. Therefore, it has strong adaptability to early-stage mild patients or mid-to-late-stage patients who require combination therapy.

For patients with newly diagnosed Parkinson's disease, especially those who are younger and have relatively mild symptoms, rasagiline can be used as the first-choice monotherapy because of its potential neuroprotective effect and its ability to delay the progression of the disease. It has been found in multiple clinical studies that early use of rasagiline can delay the initiation of levodopa to a certain extent, thereby reducing the incidence of levodopa-related motor complications.

In the treatment of mid-to-late Parkinson's disease, when patients begin to experience "drug efficacy fluctuations" or "switching phenomena", rasagiline can be used as a synergist of levodopa. By inhibiting the decomposition of dopamine, the effective time of levodopa can be extended, the symptoms of motor fluctuations can be alleviated, and the patient's daily functional performance can be improved.

In addition, rasagiline has a low threshold for use, usually does not require frequent monitoring of blood indicators, and is not prone to serious interactions with other drugs, making it suitable for elderly patients with multiple comorbidities. However, it is worth noting that before using this product, it is necessary to evaluate whether there are contraindications such as severe liver dysfunction, mental illness, or taking specific antidepressants.

Therefore, in summary, rasagiline is a safe and stable choice for patients with definite diagnosis of Parkinson's disease. It is especially suitable for patients who require early monotherapy or combination therapy in the middle and late stages.

Reference materials:https://www.azilect.com/